Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
143
-
Total 13F shares, excl. options
-
52,976,629
-
Shares change
-
-1,766,036
-
Total reported value, excl. options
-
$864,638,987
-
Value change
-
-$84,608,748
-
Put/Call ratio
-
1.25%
-
Number of buys
-
78
-
Number of sells
-
-73
-
Price
-
$16.32
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2021
195 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2021.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 143 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52,976,629 shares
of 104,661,494 outstanding shares and own 50.62% of the company stock.
Largest 10 shareholders include JPMORGAN CHASE & CO (6,926,406 shares), BlackRock Inc. (5,334,099 shares), Palo Alto Investors LP (4,369,366 shares), Capital World Investors (3,712,000 shares), VANGUARD GROUP INC (3,602,297 shares), Polar Capital Holdings Plc (2,259,700 shares), JENNISON ASSOCIATES LLC (2,203,564 shares), FRANKLIN RESOURCES INC (1,820,069 shares), STATE STREET CORP (1,566,846 shares), and Capital International Investors (1,545,630 shares).
This table shows the top 143 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.